Patent · US Active

Compositions and methods of use for therapeutic antibodies

US9340620B2 · kind B2 · utility

3Cited by

1References

5Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Christoph Heusser · Oberwil, CH
Julia Neugebauer · Munich, DE
Eveline Schaadt · Munich, DE
Stefanie Urlinger · Munich, DE
Maximilian Woisetschlaeger · Oberwil, CH

Key dates

Filing date	Dec 15, 2011
Grant date	May 17, 2016
Priority date	—
Expiry date	Jul 13, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.